A Novel Nanomedicine System TAR-AuNSs/Dox for the Treatment of Drug-Resistant Lymphoma

Figure 4

The cell viability of Daudi and Daudi/R cells treated with TAR-AuNSs/Dox. Cell viability of Daudi and Daudi/R cells with different doses of AuNSs (a) and TAR-AuNSs (b) for 24 h by CCK8. Cell viability of Daudi (c) and Daudi/R (d) cells treated with PBS, free Dox, AuNSs/Dox, and TAR-AuNSs/Dox by CCK8 assay.

(a)

(b)

(c)

(d)